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Among the factors potentially involved in delayed
xenograft rejection, xenoreactive antibodies are being
stressed as the cause of antibody-induced endothelial
cell activation4 or antibody-dependent cellular cytotox-
icity.5 If xenoantibodies should prove to be important in
the pathogenesis of delayed xenograft rejection, the
therapeutic consequences must include both the reduc-
tion of preformed (naturally occurring) xenoantibodies
before xenotransplantation and the suppression of
elicited xenoantibody production after transplantation.
Our study addresses the question of whether the
reduction of the preformed fraction of xenoantibodies
prolongs delayed xenograft rejection, provided the
complement system is completely inactivated.
Plasmapheresis is an established procedure to reduce
preformed xenoantibody levels. However, these anti-
bodies are reported to rebound a few days after plasma-
pheresis.6 On the basis of the antibody kinetics after
plasmapheresis, we xenografted decomplemented rats,
whose preformed xenoantibody levels were either
H yperacute rejection in discordant species combina-tions is mediated by preformed xenoantibodies and
the classical and alternate pathways of complement
activation.1,2 If hyperacute rejection is prevented by
complement inhibition, another type of rejection,
termed delayed xenograft rejection, will proceed over
the following days. This process is characterized by
donor endothelial cell activation, thrombosis, and infil-
tration of the graft with mononuclear cells.3
Introduction: Whereas the involvement of elicited xenoantibodies in
delayed xenograft rejection is currently being substantiated, this study
focuses on the role of the preformed fraction of xenoantibodies. Methods:
To check the influence of the latter, we combined pretransplant comple-
ment inactivation (cobra venom factor) and antibody reduction
(plasmapheresis) in a guinea pig–to–rat heart transplant model. Results:
Antibody reduction on plasmapheresis before xenografting did not pro-
long delayed xenorejection in decomplemented rats, although the
immunohistologic pattern lacked the immunoglobulin deposits along
endothelial walls found in xenografts of merely decomplemented recipi-
ents. Astonishingly, plasmapheresis, if carried out 2 days before trans-
plantation, almost tripled xenograft survival, although preformed anti-
body levels were completely restored and even rebounding at the time of
grafting. The pattern and number of infiltrating cells did not differ in
dependence of the timing of plasmapheresis nor did the proliferative
response of lymphocytes in the mixed lymphocyte reaction differ.
However, plasmapheresis led to a retarded decrease of the mononuclear
cell tumor necrosis factor α secretory potential, which correlated well
with a diminished immunohistologic staining of tumor necrosis factor α
secreted by graft-infiltrating mononuclear cells. Conclusion: These find-
ings argue against a pivotal role of preformed xenoantibodies in the
pathomechanistic process of delayed xenograft rejection and challenge
the therapeutic strategy to reduce preformed xenoantibody levels before
xenotransplantation in complement-inactivated recipients. (J Thorac
Cardiovasc Surg 2000;119:477-87)
Helmut Grimm, MD, PhDa
Petra Mages, MDa
Gertraut Lindemann, MDa
Mechthild Potthoff, MDa
Ulrich Bohnet, MDa
Stephan Korom, MDa
Leander Ermert, MDb
From the Department of General and Thoracic Surgerya and the
Institute for Pathology,b University of Giessen, Giessen, Germany.
Received for publication April 19, 1999; revisions requested July 26,
1999; revisions received Aug 20, 1999; accepted for publication
Sept 28, 1999.
Address for reprints: Helmut Grimm, MD, PhD, Department of
General and Thoracic Surgery, University of Giessen, Rudolf-
Buchheim-Strasse 7, D-35392 Giessen, Germany (E-mail: hel-
mut.grimm@chiru.med.uni-giessen.de).
Copyright © 2000 by Mosby, Inc.
0022-5223/2000 $12.00 + 0 12/1/103298
doi:10.1067/mtc.2000.103298
EVIDENCE AGAINST A PIVOTAL ROLE OF PREFORMED ANTIBODIES IN DELAYED REJECTION OF A
GUINEA PIG–TO–RAT HEART XENOGRAFT
478 Grimm et al The Journal of Thoracic and
Cardiovascular Surgery
March 2000
unmodified, reduced, or rebounding. Astonishingly,
delayed xenograft rejection time was almost tripled in
recipient rats with rebounding antibody levels. This
finding challenges the idea that delayed xenograft
rejection is mediated by naturally occurring xenoanti-
bodies and relativizes the therapeutic strategy to reduce
these xenoantibody levels before transplantation.
Material and methods
Experimental design. Reduction, renormalization, and
rebound characterize the consecutive stages of preformed
xenoantibody titers after plasmapheresis. On the basis of
these kinetics, rats with unmodified, reduced, or rebounding
xenoantibody levels underwent xenografting after the com-
plement system had been inactivated by cobra venom factor
(CVF) to elaborate the effect of preformed xenoantibodies on
delayed xenograft rejection.
Treatment groups. In a preliminary set of experiments, the
kinetics of preformed xenoreactive and total immunoglobulin
G (IgG) or IgM antibody levels, complement activity, coagu-
lation variables, mixed lymphocyte reaction, and mononu-
clear cell cytokine secretion were monitored in rats (n = 6)
after plasmapheresis.
In a second set of randomized experiments (n = 6 each
group), guinea pig hearts were transplanted into complement-
inactivated rats with unmodified (no plasmapheresis),
reduced (immediately after plasmapheresis), or rebounding
xenoantibody titers (defined time point after plasmapheresis).
Control rats without complement inactivation were matched
to each group.
Animals. The experiments were performed after approval
of the local committee of ethics and in accordance with the
“Guide for the Care and Use of Laboratory Animals,” as
revised by the National Institutes of Health in 1985.7
Inbred guinea pigs (BNF Giessen, 250-300 g) and rats
(Sprague-Dawley Hannover, 200-250 g) served as donors and
recipients in a heterotopic cardiac xenograft model. Rats used
for the preliminary kinetic studies after plasmapheresis
weighed 350 g for reasons of the repetitive blood with-
drawals. The laboratory animals were housed in plastic cages
with stainless-steel wire bottoms in a laboratory with con-
trolled temperature (20°C), humidity (50%), and 12-hour
light-dark cycle. The animals were allowed to adapt to the
environment at least 1 week before transplantation. They had
free access to R3-EWOS-ALAB Brood Stock Feed (ALAB,
Sollentuna, Sweden).
Plasmapheresis. Plasmapheresis was performed as
described elsewhere.6 Briefly, the rats were anesthetized with
phentanylcitrate 0.315 mg/kg body weight administered
intramuscularly (Hypnorm, Janssen, Belgium). Polyethylene
catheters (Clay Adams, Parsippany, NJ) were inserted in the
right carotid artery (PE-50, inner diameter: 0.58 mm, outer
diameter: 0.965 mm) and the right femoral vein (PE-60, inner
diameter: 0.76 mm, outer diameter: 1.22 mm). The blood was
forwarded through a peristaltic pump (Ismatec MS-Reglo 6;
Ismatec, Wertheim, Germany) at a flow rate of 3 mL/min
through polypropylene fiber microfilters (Fresenius SPS
1003; Fresenius, St Wendel, Germany) with an active fiber
surface of 90 cm2, an active fiber length of 16 cm, and a pore
diameter of 0.5 µm. The filtration rate was 0.3 mL/min. One
and a half plasma volumes were exchanged and replaced by
7% human albumin in physiologic saline solution. Rats not
receiving plasmapheresis were sham operated.
Blood samples were taken from the arterial catheter before,
immediately after, and 6, 9, 12, and 24 hours after plasma-
pheresis and then daily until day 7. After clotting at room
temperature for approximately 1 hour, serum was separated
from blood samples by centrifugation at 3000 rpm for 15
minutes at 0°C to 4°C and stored at –70°C until used. All sera
from an individual animal were analyzed simultaneously.
Heparinized blood samples (10 IU heparin per milliliter) for
mixed lymphocyte reactions and the assessment of the tumor
necrosis factor α (TNF-α) secretory potential of mononu-
clear cells or citrated blood samples (10% Na citrate) for the
measurement of coagulation variables were withdrawn
before, immediately after, and 2 days after plasmapheresis.
Circulating immunoglobulins. IgM and IgG were measured
by commercially available Radial Immunodiffusion Kits
according to Mancini (Camon, Wiesbaden, Germany).
Xenoreactive antibodies. Xenoreactive antibodies were
measured by an enzyme-linked immunosorbent assay
(ELISA) technique according to the method of Leventhal and
colleagues.8 Briefly, guinea pig platelets were isolated and
lysed by freezing and thawing. Platelet membranes were
extracted and centrifuged at 55,000 rpm. The supernatant was
stored at –70°C until used. Guinea pig platelet membranes
(100 µL/well of a 10 µg of protein per milliliter of prepara-
tion) were absorbed onto 96-well Polysor-P plates (Nunc,
Napperville, Ill) for approximately 12 hours at 37°C. Serial
dilutions of the primary antibody solution were added to the
wells. After an incubation for 2.5 hours, the secondary anti-
body (rabbit anti-rat IgM [µ-chain specific] or rabbit anti-rat
IgG [γ-chain specific]) conjugated to alkaline phosphatase
(dilution 1:500; Zymed Co, San Francisco, Calif) was added.
The developing solution consisted of 1 mg/mL p-nitrophenyl
phosphate and 100 mmol/L diethanolamine in 0.5 mmol/L
MgCl2. The absorbance was determined at a wavelength of
405 nm.
Complement activity. Total complement activity was mea-
sured as hemolytic activity according to the method of
Mayer.9
Coagulation variables. Activated partial thromboplastin
time, thrombin time, and prothrombin time were assessed
from citrated whole blood (10% Na citrate), as described
elsewhere.10-12
TNF-α secretory potential of mononuclear cells.
Heparinized fresh whole blood (10 IU heparin/mL) was dilut-
ed 1:2 with phosphate-buffered saline solution (PBS). The
peripheral blood mononuclear cell (PBMC) fraction was
obtained by Ficoll-Hypaque centrifugation. The cells were
washed in PBS before culturing. The PBMCs were cultured
for 24 hours at 37°C at a density of 1 × 106 cells/well in
RPMI supplemented with 5% (vol/vol) fetal calf serum
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unstimulated or after the addition of 25, 50, or 100 µg of con-
canavalin A. The supernatant was collected after centrifuga-
tion at 2000 rpm for 10 minutes. The concentration of TNF-α
in PBMC culture media was assayed by using a commercial
murine TNF-α ELISA kit (Endogen Inc, Boston, Mass).
Mixed lymphocyte reaction. Lymphocytes were separated
from heparinized blood by density gradient centrifugation.
Guinea pig stimulator cells and syngeneic rat lymphocytes
were incubated with mitomycin C (final concentration, 25
µg/mL) in a humidified 5% carbon dioxide incubator at 37°C
for 30 minutes. One hundred microliters of both the respon-
der and the stimulator cell suspensions (1 × 106 cells/mL)
was pipetted in each well of the microtiter plate and incubat-
ed for 5 days at 37°C (5% carbon dioxide at 90% humidity).
Mitogen-stimulated controls were incubated with con-
canavalin A (final concentration, 25 µg/mL). After incubation
with 10 µL/well bromodeoxyuridine and centrifugation at
300g for 10 minutes, the labeling medium was flicked off.
After denaturation by formamide, each well was filled with
100 µL of monoclonal anti-bromodeoxyuridine. One hundred
microliters of peroxidase-conjugated rabbit anti-mouse
immunoglobulin was added to each well (diluted 1:1000 in
PBS-Tween). After a 30-minute incubation, 100 µL of perox-
idase substrate solution was added to each well. The enzy-
matic reaction was stopped after 10 minutes by the addition
of 25 µL of 1 mol/L H2SO4. The intensity of the color reac-
tion was read in an automatic ELISA plate reader (Titertek
Multiscan MC) by using a 492-nm filter.
Complement depletion. CVF (Naja naja) was purchased
from Sigma Chemical Company (St Louis, Mo). A 1-step
procedure with fast protein liquid chromatography13 was
used to isolate phospholipase A2–free CVF. Complement-
depleting activity was determined in Bellow and Cochrane
units.14 Fifty units of CVF per kilogram of body weight was
administered every 8 hours in a 5-minute intravenous infu-
sion. For that purpose, a 5-cm long, spiral-shaped piece of
PE-10 catheter (Clay Adams, Parsippany, NJ) attached to a
silicone tube (Silastic 0.012 in × 0.025 in, No. 602-105 HH
061999; Dow Corning Corp, Midland, Mich) was fused to a
30-cm piece of a PE-20 catheter. The silicone part of the
catheter was placed in the animal’s left jugular vein, as
described elsewhere,15 and the PE-20 end was diverted to the
exterior.
Transplantation technique. The abdomen was opened by
a midline incision, the left kidney was removed, and the kid-
ney vessels were cuffed, as described elsewhere.16 The
donors underwent anesthesia with pentobarbital 60 mg/kg of
body weight administered intraperitoneally (Mebumal vet,
Nord Vacc, Sweden). Heparin in a dose of 300 IU was inject-
ed intravenously before harvesting the heart. The grafts were
flushed with cold Ringer lactate solution containing heparin
in a concentration of 50 IU/mL. Immediately after being har-
vested, the graft was anastomized with the cuffed vessels.
Assessment of graft rejection. The transplanted hearts
were palpated hourly. Rejection was considered to be com-
plete when no more pulsations were palpable. Rejection was
confirmed histologically.
Immunohistology. Cardiac xenografts were snap-frozen in
isopentane. Cryostat sections of 7 µm were cut, air-dried on
gelatinized slides, and fixed in acetone. The sections were
incubated with anti-rat monoclonal or monospecific poly-
clonal antibodies directed against all leukocytes (CD45, OX-
1); B cells (CD45R, OX-33); T cells (CD5, OX-19); T cells,
polymorphonuclear neutrophils, and natural killer (NK) cells
(W 3-13); T-helper cells (CD4, W 3-25); cytotoxic T cells
(CD 8, OX-8; Camon Co, Wiesbaden, Germany); IgG, IgM,
fibrin, and C3 (ICN, Irvine, CA); and TNF-α (Genzyme
Corp, Boston, Mass) at room temperature for 30 minutes
(dilution 1:100 and 1:2500 TNF-α). The second incubation
with the appropriate immunoglobulin-bridging antibodies
(diluted 1:20) was at room temperature for 30 minutes. After
incubation with alkaline phosphatase—antialkaline phos-
phatase complex (diluted 1:50), the coloration was developed
with alkaline-phosphatase substrate. Sections were counter-
stained with hemalaun. Labeled cells within 20 high-power
fields per section per rat were counted by blinded observers
with the aid of an ocular grid micrometer (Leitz Co, Wetzlar,
Germany). Depending on the cellular count, the mononuclear
cell infiltrate was considered to be scarce (+), moderate (++),
or marked (+++). Cytokine labeling was expressed semi-
quantitatively (<1%, <5%, 10%-20%, 20%-50%, or >75% of
the cells indicated) because of the presence of extracellular
labeling. The specificity of labeling was assessed by using
multiple controls.
Isotype-matched monoclonal antibodies or purified
immunoglobulin and a control for endogenous phosphatase
activity were included in each experiment, and studies were
undertaken to confirm the lack of labeling of normal guinea
pig hearts (n = 5) with the antibodies used. Additional sam-
ples were fixed in neutral-buffered formalin, embedded in
paraffin, and sectioned for light microscopy.
Statistics. Differences between the groups in graft sur-
vival, PBMC cytokine release, and mixed lymphocyte reac-
tion were analyzed by using the Student t test after a normal
distribution had been confirmed by using the Kolmogorov-
Smirnov test. The Mann-Whitney U test was used to compare
immunohistologic differences between the different groups.
The Bonferroni procedure was applied to adjust for repeated
comparisons. For all other determinations, 1-way analysis of
variance with the Tukey honestly-significant-difference post
hoc test was used to test for differences between the various
groups after a normal distribution had been confirmed with
the Kolmogorov-Smirnov test. Values are presented as means
± SD.
Results
Kinetics after plasmapheresis 
Antibody titers. In the thrombocyte-targeted ELISA,
rat anti-guinea pig antibodies proved to be of the IgM
isotype. The unspecific binding of the secondary rabbit
anti-rat IgG antibodies resulted only in serum dilu-
tion–independent background levels. Plasmapheresis
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reduced total IgM, total IgG, and xenoreactive antibody
titers to less than 30% of their previous levels. Total IgM
(Fig 1, B), but not total IgG (Fig 1, C), levels paralleled
exactly the post-therapeutic kinetics of preformed
xenoantibody levels (Fig 1, A). Two days after plasma-
pheresis, xenoantibody levels were restored to prethera-
peutic values (Fig 1, A) followed by a slight rebound.
Complement activity. Complement activity was
reduced to around 30% of the pretherapeutic level and
renormalized within 5 days (Fig 2). In case of addi-
tional or exclusive complement inactivation by short-
term infusion of CVF (50 U/kg of body weight every 8
hours), complement activity decreased below the detec-
tion limit as long as the therapy was continued.
Coagulation variables. Before plasmapheresis, acti-
vated partial thromboplastin time was 18 ± 1 seconds,
thrombin time was 26 ± 1 seconds, and prothrombin
time was greater than 120%. Immediately after plasma-
pheresis, activated partial thromboplastin time and
thrombin time were prolonged to 35 ± 2 seconds (P <
.001) and 32 ± 2 seconds (P = .008), respectively, and
prothrombin time was reduced to 58% ± 3% (P < .001).
Two days after plasmapheresis, coagulation variables
were renormalized.
PBMC TNF-α secretory potential. Secretion of TNF-
α by PBMCs immediately after plasmapheresis was
maximal on stimulation with 12.5 µg of concanavalin
A (285 ± 60 pg/106 PBMCs). Two days after plasma-
pheresis, maximum TNF-α secretion was 75 ± 11
pg/106 PBMCs (P = .0098) after stimulation with 25 µg
of concanavalin A (Fig 3).
Mixed lymphocyte reaction. The proliferative
response of rat lymphocytes to mitogen, syngeneic
lymphocytes, or guinea pig lymphocytes remained
unchanged before, immediately after, and 2 days after
plasmapheresis, respectively (P > .2 between the dif-
ferent groups, Fig 4). There was no significantly differ-
ent proliferation of rat lymphocytes on co-cultivation
with guinea pig lymphocytes in comparison with syn-
geneic lymphocytes (P > .2).
Transplant design on the basis of the preliminary
studies. On the basis of the preliminary studies, xeno-
transplantation was performed without plasmapheresis
(unmodified preformed xenoantibody level, Fig 5, A),
immediately after plasmapheresis (reduced xenoanti-
bodies, Fig 5, B), or 2 days after plasmapheresis
(rebounding xenoantibodies, Fig 5, C) in combination
Fig 1. Kinetics of natural antibody (A), total IgM (B), and
total IgG levels (C) after plasmapheresis in rats. Values
shown are means ± SD of 6 independent experiments. SD
bars are missing when interfering with or falling into symbol.
Arrows mark the end of plasmapheresis.
A
B
C
Fig 2. Kinetics of complement activity (C’H 50) after
plasmapheresis in rats. Values are shown as means ± SD of 6
independent experiments. SD bars are missing when interfer-
ing with or falling into symbol. Arrow marks the end of
plasmapheresis.
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with complement inactivation by CVF (Fig 5, A´, B´,
and C´).
Transplant survival. A synopsis of the therapeutic
regimen, the resulting parameters at the time of trans-
plantation, and xenograft survival is presented in Table I.
Guinea pig hearts were rejected after 13.4 ± 4.5 min-
utes in unmodified rats. Transplant survival was pro-
longed to 4.9 ± 1.2 hours in rats pretreated with
plasmapheresis (P < .001 vs unmodified recipients).
Plasmapheresis 2 days before transplantation resulted
in a graft survival time of 15 ± 4.7 minutes (P > .2 vs
unmodified recipients).
Rats treated with CVF rejected the grafts after 31.8 ±
2 hours (P < .001 vs unmodified recipients). CVF com-
bined with pretransplant plasmapheresis caused a
transplant survival of 28 ± 6.1 hours (P < .001 vs
plasmapheresis, P > .2 vs CVF).
Plasmapheresis 2 days before transplantation com-
bined with CVF immediately after transplantation pro-
longed graft survival to 72 ± 9.7 hours (P < .001 vs
plasmapheresis 2 days before transplantation, P < .001
vs plasmapheresis plus CVF).
Histologic and immunohistologic evaluation of
rejected xenografts. In unmodified rats and rats treat-
ed with plasmapheresis, extensive hemorrhage and
edema were seen throughout the myocardium of reject-
ed xenografts besides capillary and venular congestion
and platelet thrombi. The immunohistologic examina-
tion revealed focal capillary deposits of IgM and dif-
fuse deposits of C3 and fibrin layers along endothelial
surfaces of small and large blood vessels. IgG was scat-
tered in the interstitium of the tissue. No infiltrating
cells were detected (Table II).
Rejected xenografts from CVF-treated rats showed
areas of hemorrhage and migration into the myocardi-
um of monocytes and granulocytes. The pattern of IgM,
IgG, and fibrin deposition was essentially identical to
that described above. Staining for C3 was negative.
Fig 3. TNF-α secretory potential on stimulation with various
amounts of concanavalin A (Con A) of PBMCs harvested
from rats (n = 6 for each group) immediately or 2 days after
plasmapheresis (PP). Values are given as means ± SD. SD
bars are missing when interfering with or falling into symbol.
Fig 4. Proliferative response on stimulation with syngeneic
rat lymphocytes (negative control), xenogeneic guinea pig
lymphocytes, and concanavalin A (positive control) of lym-
phocytes harvested from rats (n = 6 for each group) before
(A), immediately after (B), and 2 days after (C) plasma-
pheresis, as measured by immunoenzymatic reactivity for
bromodeoxyuridine incorporation (optical density [o.d.] at
492 nm wave length). *P > .2 among the different therapeu-
tic groups; #P > .2 within a given group.
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Fig 5. Graphic representation of the different xenotransplantation settings in relation to the kinetics of preformed
xenoantibodies (filled circles) and complement activity (plus signs), as determined in preliminary studies. The
arrow (Tx) marks the time point when xenotransplantation was drafted without plasmapheresis (A) (unmodified
preformed xenoantibody level), immediately after plasmapheresis (B) (reduced preformed xenoantibodies), or 2
days after plasmapheresis (C) (rebounding preformed xenoantibodies) and in combination with complement inac-
tivation by CVF (A´, unmodified preformed xenoantibody level with the complement inactivated; B´, reduced
preformed xenoantibodies with the complement inactivated; C´, rebounding preformed xenoantibodies with the
complement inactivated). Values on the right side of the arrow actually do not represent measurements after
xenografting but characterize the kinetics as they occur in the different therapeutic settings without transplanta-
tion. For reasons of clarity, SDs, which can be depicted from Figs 1 and 2, are not presented. Values are given in
relation to the starting point, which is set at 1.0.
A A´
B B´
C C´
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Plasmapheresis in combination with CVF did not
essentially change the immunohistologic rejection pat-
tern, apart from diminished IgM deposits along
endothelial walls, when both treatments were applied
simultaneously.
TNF-α labeling of intragraft mononuclear cells,
however, was markedly increased (>75% of infiltrating
mononuclear cells) in the group treated with plasma-
pheresis and CVF simultaneously (Fig 6, A) compared
with the group that underwent plasmapheresis 2 days
before CVF application and xenotransplantation (10%-
20% of infiltrating mononuclear cells; Fig 6, B).
Discussion
Activated complement causes the fulminant destruc-
tion of xenografts in discordant species, which is called
hyperacute rejection. Complement is activated by pre-
formed xenoantibodies through the classical pathway1
and through the antibody-independent alternative path-
way, with the influence of the latter varying with the
species combination.2 Inactivation of both the classical
and alternative pathway by CVF abrogates hyperacute
rejection, giving way to a milder rejection process
called delayed xenograft rejection, which is terminated
after several days.3 We found, as others did before,3,17
the immunohistologic pattern of delayed xenograft
rejection to be characterized by lacking C3 and abun-
dant immunoglobulin deposits along the endothelial
surfaces and a marked mononuclear cell infiltrate,
which is predominated by activated macrophages and
NK cells and associated with large amounts of
cytokines (eg, TNF-α). Thus there are mechanisms
apart from complement activation that lead to a some-
what prolonged xenograft rejection and presumably
Table I. Synopsis of the therapeutic regimen, the parameters at the time of xenografting, and the resulting graft
survival
Resulting parameters at the time of xenografting
Therapeutic Preformed Complement PBMC 
regimen xenoantibodies activity Coagulation TNF-α secretion MLR Graft survival
None ↑↓ ↑↓ ↑↓ ↑↓ ↑↓ 13.4 ± 4.5 min
PP ↓ ↓ ↓ ↑ ↑↓ 4.9 ± 1.2 h
PP+2d ↑ ↑↓ ↑↓ ↓ ↑↓ 15 ± 4.7 min
CVF ↑ ↓ Ø ↑↓ ↑↓ ↑↓ 31.8 ± 2 h
PP+CVF ↓ Ø ↓ ↑ ↑↓ 28 ± 6.1 h
PP+2d+CVF ↑ Ø ↑↓ ↓ ↑↓ 72 ± 9.7 h
PP, Xenotransplantation immediately after plasmapheresis; PP+2d, xenotransplantation 2 days after plasmapheresis; CVF, xenotransplantation in decomplemented
rats; PP+CVF, xenotransplantation in decomplemented rats immediately after plasmapheresis; PP+2d+CVF, xenotransplantation in decomplemented rats 2 days after
plasmapheresis; ↓, reduced level; ↑↓, unchanged level; ↑, rebounding level; Ø, level below detection limit.
Table II. Immunohistologic features of guinea pig cardiac xenografts harvested from rats either unmodified or
prone to different therapeutic regimens
Features of the rejected xenografts
Therapeutic 
Lymphocytes
regimen C3 IgM IgG Fibrin CD45 leucocytes B CD5 CD4 CD8 TNF-α
None +++ +++ + +++ — — — — — —
PP ++ + + +++ — — — — — —
PP+2d +++ +++ + +++ — — — — — —
CVF — +++ + +++ +++ ++ ++ ++ ++ >75% MNC
PP+CVF — + + ++ +++ + + + + >75% MNC*
PP+2d+CVF — +++ ++ +++ +++ + + + + ~10%-20% 
MNC*
Deposits of C3, immunoglobulin, and fibrin and cellular infiltrates were considered to be scarce (+), moderate (++), or marked (+++). TNF-α labeling was expressed
semiquantitatively (<1%, <5%, 10%-20%, 20%-50%, or >75% of the cells indicated). PP, Xenotransplantation immediately after plasmapheresis; PP+2d, xeno-
transplantation 2 days after plasmapheresis; CVF, xenotransplantation in decomplemented rats; PP+CVF, xenotransplantation in decomplemented rats immediately
after plasmapheresis; PP+2d+CVF, xenotransplantation in decomplemented rats 2 days after plasmapheresis; MNC, mononuclear cell.
*For documentation, see Fig 6, A and B.
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precede T cell–mediated defense processes known
from acute rejection. One of the initial steps of this
delayed form of xenograft rejection seems to be donor
organ endothelial cell activation, which is characterized
by transcriptional induction of genes and subsequent
protein synthesis, resulting in the expression of adhe-
sion molecules, cytokines, and procoagulant mole-
cules.18 Apart from cytokines or mitogens,19 xenoanti-
bodies have been shown in vitro to activate endothelial
cells.20 On the other hand, xenoreactive antibodies are
reported to facilitate the adhesion of NK cells to
endothelial cells and the eventual lysis of endothelial
cells in in vitro studies.21,22
Under the hypothesis that xenoreactive antibodies are
involved in delayed xenograft rejection, the pretrans-
plant reduction of naturally occurring preformed
xenoantibodies, the posttransplant inhibition of
induced xenoantibody production, or both should fur-
ther prolong delayed xenograft rejection. Our study
concentrates on the preformed fraction of xenoantibod-
ies and does not examine the role of specific xenoanti-
bodies induced after xenografting.
Plasmapheresis proved to be a nonspecific but effec-
tive method to reduce natural xenoantibodies. In our
preliminary kinetic studies the initial reduction of pre-
formed xenoantibodies to below 30% of their original
level was followed by an antibody rebound 2 days after
plasmapheresis, which confirmed analogous results in
the literature.6 Like others,23 we found a correlation
between the titers of naturally occurring antiendothelial
cell antibodies and the concentrations of IgM because
the kinetics of both exactly paralleled each other after
plasmapheresis. Supporting this finding, IgM, and not
IgG, turned out to be the isotype of preformed xenore-
active antibodies in our model, as shown in the throm-
bocyte-targeted ELISA. There seem to be species-relat-
ed differences in the isotype of naturally occurring
xenoreactive antibodies. Although preformed rat anti-
guinea pig antibodies are commonly reported to belong
to the IgM subclass,24 naturally occurring human anti-
pig antibodies are believed to be mostly IgG.25 On the
other hand, specific xenoantibodies induced after xeno-
transplantation by immunization seem to belong to
both the IgG and IgM classes.26 Because of its non-
specificity, plasmapheresis reduced not only antibody
levels but also coagulation factors and complement
components, resulting in a temporary impairment of
both the coagulation system and the complement activ-
ity, which were basically restored within 2 days.
Pretransplant plasmapheresis prolonged hyperacute
rejection in our model from minutes to several hours by
reducing preformed xenoantibodies and the activities
of both the complement and the coagulation systems.
Two days after plasmapheresis, when the above-men-
tioned parameters are renormalized, hyperacute rejec-
tion occurs in the same fulminant way as in unmodified
recipients, giving clinical proof that the parameters
accounting for hyperacute rejection were sufficiently
restored.
The situation changes completely when plasma-
pheresis is administered in both above-mentioned time
settings, provided hyperacute rejection has been abro-
gated by CVF. If combined with CVF-induced comple-
ment inactivation, plasmapheresis exerted immediately
after transplantation did not result in a prolongation of
xenograft survival nor in an alteration of the immuno-
histologic rejection pattern apart from reduced
immunoglobulin deposits along endothelia. However,
delayed xenograft rejection was prolonged from an
average of 28 to 72 hours when rats received plasma-
Fig 6. Photomicrographs of immunophosphatase labeling of
guinea pig cardiac xenografts from decomplemented rats
treated with plasmapheresis immediately before (A) or 2 days
before (B) transplantation. TNF-α labeling of cryostat sec-
tions (original magnification, ×400) is distinctly diminished
in B compared with A.
A
B
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pheresis 2 days before CVF application and subsequent
transplantation. From the perspective of a pathogenetic
role of preformed antibodies in delayed xenograft
rejection, this finding was absolutely surprising
because in animals treated with plasmapheresis and
CVF simultaneously, xenotransplantation was per-
formed in a decomplemented organism with preformed
xenoantibody levels minimized, whereas rats undergo-
ing plasmapheresis 2 days before the application of
CVF and grafting represented a decomplemented host
with renormalized xenoantibody levels, even being on
the threshold of a rebound production. Although these
results do not exclude endothelial cell activation nor
antibody-dependent cellular cytotoxicity mechanisms
by preformed xenoantibodies, which were reported
previously,20,21 they question the relevance of these
processes in delayed xenograft rejection, at least with-
in the observed time range of 72 hours. Meanwhile,
there are rising doubts that preformed xenoreactive
antibodies are pathogenetically involved in delayed
xenograft rejection. NK cells have been found to acti-
vate endothelial cells with and without the involvement
of natural xenoantibodies,18 probably because of a par-
tial overlap of the xenogeneic structures recognized by
NK cells and xenoreactive natural antibodies.27 NK
cells were also shown to adhere to and efficiently lyse
xenogeneic endothelium both in the presence and
absence of xenoreactive natural antibodies.21 Inter-
actions between accessory molecule receptor-ligand
pairs on NK cells, macrophages and xenogeneic
endothelium seem to be of critical importance in
delayed xenograft rejection.28 These processes might
be readily enhanced because NK cells proliferate in the
presence of xenogeneic endothelial cells.29 Although
our study data question the necessity to reduce natural
xenoantibodies before transplantation to prolong
delayed xenograft rejection, they do not deal with a
possible involvement of induced xenoantibodies in this
process. In comparison with preformed xenoantibod-
ies, which are known to be polyreactive,30 endothelial
cell activation and antibody-dependent cellular cyto-
toxicity mechanisms caused by the much more specif-
ic induced xenoantibodies31 might be relevant patho-
genetic factors in delayed xenograft rejection.
Our results demonstrate that plasmapheresis admin-
istered immediately before transplantation with the
intention to minimize preformed xenoantibodies or to
impair coagulation activity is not an effective therapeu-
tic procedure to prolong delayed xenograft rejection in
decomplemented hosts. However, the question remains
why plasmapheresis proved effective when exerted 2
days before xenotransplantation. Apparently, plasma-
pheresis leads to a retarded and delayed reduction of
parameters that account for xenograft failure beyond
hyperacute rejection.
Specific cellular rejection mechanisms can be ruled
out because the immunohistologic examination of the
xenografts rejected after an average of 72 hours pre-
sented only mild T-cell infiltrates far apart from the cel-
lular rejection pattern known from allograft rejection.
Besides, major T-cell involvement is not to be expected
in such an early stage of rejection.
On the other hand, xenogeneic helper T-cell respons-
es were demonstrated to be weaker than allogeneic
responses, at least by some authors.1 In accordance, no
relevant proliferation of rat lymphocytes on co-culture
with guinea pig lymphocytes was to be observed in our
mixed lymphocyte reaction. The failure to proliferate
may be due to a defective CD4+ T helper cell-xenoanti-
gen interaction or the failure of certain lymphokines to
function across species differences, as suggested by the
observation that primary xenogeneic cytotoxic respons-
es were reconstituted by exogenous syngeneic, but not
xenogeneic, growth factors.32 Thus it may well be that
T cell–mediated responses to xenografts are weaker
than those to allografts, although there are conflicting
results in models other than guinea pig to rat.33
Our grafts prone to delayed xenograft rejection con-
tained an infiltrate of mononuclear cells other than T
cells. This corresponds well with other studies, which
found polymorphonuclear neutrophils, macrophages,
and NK cells to be the predominant types of graft-infil-
trating cells in delayed xenograft rejection.1 Adoptive
transfer of macrophages from rat recipients of a first
xenograft to a CVF-treated naive rat has been shown to
accelerate the rejection of a discordant xenograft of the
same donor species.34 Even in the absence of xenoanti-
bodies, T cell– and NK cell–activated macrophages
were found to be able to reject xenografts, probably
because of TNF-α–associated endothelial cell activa-
tion.35 Exposure of cultured endothelial cells to TNF-α
has been demonstrated to cause a series of changes in
the cells, including the expression of new cell surface
proteins and modifications in the permeability of the
cell monolayer to plasma proteins and blood cells,
which together are called endothelial cell activation.36
In fact, the TNF-α secretory potential of mononu-
clear cells proved to be markedly reduced 2 days after
plasmapheresis compared with immediately after
plasmapheresis. Seemingly, the procedure of plasma-
pheresis stimulates mononuclear cells to increase the
spontaneous TNF-α secretory output, which may come
true for other cytokines as well, eventuating in a retard-
ed exhaustion 2 days thereafter. The kinetics of
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cytokine secretion after plasmapheresis has hitherto not
been studied, but previous studies indicated a rise in
plasma anaphylatoxins on hemodialysis.37 Among
other factors that have not been examined in this study,
the delayed secretory exhaustion of mononuclear cells
might explain the prolonged xenograft rejection 2 days
after plasmapheresis because of the impaired TNF-α
secretion on the stimulus of xenotransplantation.
Correspondingly, TNF-α was, to a much lesser degree,
stained immunohistologically compared with the
experimental group, in which plasmapheresis was car-
ried out immediately before grafting.
In summary, delayed xenograft rejection appears to
proceed in the absence of detectable complement acti-
vation. The role of xenoantibodies in this process is
currently being examined. Our study results strongly
argue against a pivotal role of the preformed fraction of
xenoreactive antibodies, provided the complement sys-
tem is completely inactivated, whereas adoptive trans-
fer experiments substantiate the involvement of
induced xenoantibodies.38 Thus the therapeutic strategy
to reduce preformed xenoantibodies before xenograft-
ing is challenged. Emphasis has to be put on inhibiting
the production of the more specific elicited xenoanti-
bodies after transplantation.
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